Circulating tumor cells following first chemotherapy cycle: An early and strong predictor of outcome in patients with metastatic breast cancer

Oncologist

Volumn 18, Issue 8, 2013, Pages 917-923

  Martín, Miguel ^a   Custodio, Sara ^a   Maestro De Las Casas, Maria Luisa ^b   García Sáenz, José Ángel ^b   De La Torre, Julio César ^b   Bellón Cano, Jose María ^a   López Tarruella, Sara ^a   Vidaurreta Lazaro, Marta ^b   De La Orden, Virginia ^b   Jerez, Yolanda ^a   Márquez Rodas, Iván ^a   Casado, Antonio ^b   Sastre, Javier ^b   Díaz Rubio, Eduardo ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Circulating tumor cells; Metastatic breast cancer; Outcome prediction

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; LAPATINIB; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST METASTASIS; CIRCULATING TUMOR CELL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

CIRCULATING TUMOR CELLS; METASTATIC BREAST CANCER; OUTCOME PREDICTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84883222526     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0479     Document Type: Article

References (9)

1. Pierga JY, Bonneton C, Vincent-Salomon A et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral and bone marrow breast cancer patients. Clin Cancer Res 2004;10:1392-1400.
2. Cristofanilli M, Budd GT, Ellis M et al. Circulating tumor cells, disease progression and survival in metastatic breast cancer. N Engl JMed 2004;351:781-791.
3. Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-6409.
4. Cristofanilli M. Circulating tumor cells, disease progression and survival in metastatic breast cancer. Semin Oncol 2006;33:S9-S14.
5. Martín M, García-Saenz JA, Maestro ML et al. Circulating tumor cells in metastatic breast cancer: timing of bloodextraction. Anticancer Res 2009;29:4185-4187.
6. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
7. Pierga JY, Hajage D, Bachelot T et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2011;23:618-624.
8. Liu MC, Shields PG, Warren RD et al. Circulating tumor cells:Auseful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009;27: 5153-5159.
9. Giordano A, Giuliano M, De Laurentis M et al. Circulating tumor cells in inmunohistochemical subtypes of metastatic breast cancer: Lack of prediction in HER-2-positive disease treated with targeted therapy. Ann Oncol 2012;23: 1144-1150.